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Abstract
Introduction: Normal function of the p53 network is lost in most cancers, often through p53 mutation. The clinical
impact of p53 mutations in breast cancer remains uncertain, especially where p53 isoforms may modify the effects
of these p53 mutations.
Methods: Expression of p53b and p53g isoforms, the isoforms identified in normal breast tissue, was detected by
reverse transcription polymerase chain reaction from a cohort of 127 primary breast tumours. Expression of p53b
and p53g isoforms was analysed in relation to clinical markers and clinical outcomes (5 years) by binary logistic
regression, Cox proportional hazards regression and Kaplan-Meier survival analyses.
Results: p53b and p53g were not randomly expressed in breast cancer. p53b was associated with tumour
oestrogen receptor (ER) expression, and p53g was associated with mutation of the p53 gene. The patient group
with the mutant p53 breast tumour-expressing p53g isoform had low cancer recurrence and an overall survival as
good as that of patients with wild-type p53 breast cancer. Conversely, patients expressing only mutant p53,
without p53g isoform expression, had a particularly poor prognosis.
Conclusions: The determination of p53g expression may allow the identification, independently of the ER status, of
two subpopulations of mutant p53 breast cancer patients, one expressing p53g with a prognosis as good as the
wild-type p53 breast cancer patients and a second one not expressing p53g with a particularly poor prognosis. The
p53g isoform may provide an explanation of the hitherto inconsistent relationship between p53 mutation,
treatment response and outcome in breast cancer.
Introduction
T h ep 5 3p a t h w a yi su b i q u i t o u s l ya b n o r m a li nh u m a n
cancers, either through mutation of the p53 gene or via
modification of p53 function by interaction with onco-
genic cellular or viral proteins [1,2]. Somatic p53 gene
mutations, found in about 25% of breast cancers, are
associated with poor prognosis [3,4]. Patients bearing
mutant p53 breast cancer have resistance to several che-
motherapy agents but may be more sensitive to taxanes,
at least in the neoadjuvant setting [5-10]. However, the
uncertainties around the relationships between p53
mutation, therapeutic response and outcome in breast
cancer suggest that additional factors may be involved.
The human p53 gene expresses at least nine different
p53 protein isoforms containing different domains of
the p53 protein (p53, p53b,p 5 3 g, Δ133p53a, Δ133p53b,
Δ133p53g, Δ40p53a, Δ40p53b and Δ40p53g)a sar e s u l t
of multiple splicing, alternative initiation of translation
and internal promoter usage [11-13]. The p53 isoforms
are differentially expressed in normal human tissues,
with normal breast tissue expressing p53, p53b and
p53g [13]. Abnormal expression of p53 isoforms has
been identified in several human cancer types [13-19].
We have previously reported that p53 isoforms such as
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suppressor activity [13,19,20]. Taken together, these
findings suggest that the p53 isoforms may play a role
in human cancers.
In this report, expression of the p53b and p53g iso-
forms is examined in relation to clinical and pathologi-
cal markers, p53 mutation and disease outcome in a
cohort of 127 randomly selected primary breast
tumours. The patient group expressing the p53g isoform
had abrogation of the poor prognostic effect associated
with p53 mutation, with a low risk of cancer recurrence
and a survival rate as good as that of the patient group
bearing wild-type p53 breast cancer. Conversely, patients
expressing only mutant p53,w i t h o u tp 5 3 g isoform
expression, had a particularly poor prognosis. The p53g
isoform may explain the inconsistent relationship
between p53 mutation and breast cancer in the
literature.
Materials and methods
Clinical samples
Previously untreated operable primary breast cancer in
127 Caucasian women (age range, 32 to 89 years; med-
ian age, 60 years) with sufficient tumour tissue surplus
for diagnostic requirements and complete clinical and
pathological data was analysed. Tumour tissues were
macrodissected by a specialist breast pathologist and
snap-frozen in liquid nitrogen prior to storage at -80°C.
Samples were examined following Local Research Ethics
Committee approval under delegated authority from the
Tayside Tissue Bank. The Tayside Tissue Bank has
received ethical approval for its activities (REC Refer-
ence 07/S1402/90).
Reverse transcription-polymerase chain reaction analysis
Approximately 10 mg of tumour tissue (>40% of
tumour cells) was homogenised in 750 μLo fQ I A z o l
lysis reagent (Qiagen Ltd, Crawley, West Sussex, UK),
and total RNA was extracted (Qiagen). RNA quality
was assessed using the BioAnalyzer 2100™ (Agilent
Technologies, Palo Alto, CA, USA) prior to reverse
transcription-polymerase chain reaction (RT-PCR) ana-
lysis, and all samples with a 28S:18S ratio <1.2 were
discarded. RT was performed with 0.5 μgo ft o t a lR N A
using the Cloned AMV Reverse Transcription Kit
(Invitrogen, Paisley, UK), and cDNA quality was con-
firmed by PCR amplification of actin. Samples for
which actin could not be amplified after 30 cycles of
PCR were discarded. p53 isoform cDNA was amplified
by two consecutive PCR assays (nested PCR) of
30 cycles each, and the PCR primers used were specific
for each of the p53 isoforms analysed. The different
primers used and their corresponding sequences are
indicated in Table S1 in Additional file 1. To determine
p53g mutation status, the entire open reading frame of
the isoform was sequenced using the Sanger method
(BigDye Terminator, ABI 3730 Genetic Analyser;
(Applied Biosystems, Warrington, UK) with the pri-
mers JWF (5’-AGCCAAGTCTGTGACTTGCA) and
MP9ER (5’-TCTCCCAGGACAGCACAAA CACG).
p53 mutation analysis
The p53 mutation status was determined using 100 ng
of genomic DNA extracted from homogenised frozen
tissues as described previously using the AmpliChip p53
Test (Roche Diagnostics, Pleasanton, CA, USA) [21].
Tumour grade, oestrogen receptor, progesterone
receptor and HER2 status
Immunohistochemical staining was carried out on 4-μm
sections of formalin-fixed, paraffin-embedded tumours
with the mouse monoclonal anti-oestrogen receptor a
(ER) antibody 6F11 (Novocastra Laboratories Ltd, New-
castle upon Tyne, UK), progesterone receptor (PR) anti-
body clone 16 (Novocastra Laboratories Ltd) and mouse
monoclonal anti-HER2 antibody CB11 (Novocastra
Laboratories Ltd). Additional analyses were performed
according to histological tumour grade (graded by a spe-
cialist consultant breast pathologist); pathological
tumour size (pT1, tumours <2 cm; pT2 and pT3
cancers, tumours ≥2 cm) [22]. ER status (ER negative
0 to 3 versus ER positive 4 to 18) was determined using
the quickscore method [23]. Briefly, immunoreactivity
scored semiquantitatively for both the intensity and the
proportion of cells staining. Intensity was given scores
from 0 to 3 (no staining = 0, light staining = 1, moder-
ate staining = 2 and strong staining = 3) and proportion
was given scores from 1 to 6 (0% to 4% = 1, 5% to
20% = 2, 21% to 40% = 3, 41% to 60% = 4, 61% to
80% = 5 and 81% to 100% = 6). The two scores were
then multiplied to obtain the final result of 0 to 18.
Human epidermal growth factor receptor 2 (HER2)
scoring was performed as previously described [24].
Statistical analysis
The primary outcomes in this study were breast cancer-
specific overall survival (abbreviated to overall survival)
and breast cancer-specific disease-free survival (abbre-
viated to disease-free survival or cancer recurrence
throughout the text), and accordingly, non-breast cancer
deaths were censored at the time of death (that is, at
the time of death, the women were considered to have
survived breast cancer but died as a result of other
causes). Statistical analysis was performed using Minitab
version 15.1.0.0 statistical software (Minitab Inc., PA
16801-3008, USA) for c
2,t w o - s i d e dF i s h e r ’s exact test
and Kaplan-Meier analyses. These univariate analyses
test for associations between variables in a pairwise
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out adjusting for influences exerted by other associated
variables (for example, both A and B may be associated
with confounding variables C, D and E, casting doubt
on the validity of the relationship between A and B).
To clarify the univariate analyses and adjust for possi-
ble confounding variables, the selected variables were
interrogated using the multivariate methods of binary
logistic regression (BLR) with associated odds ratios
(OR) and the Cox proportional hazards regression
model (CR) with associated risk ratios (RR), both utilis-
ing the backwards stepwise elimination method. (For
more detailed methods, read the “method” section in
Additional file 2.)
In the tables of results for these multivariate analyses,
the b value is a regression coefficient that indicates the
strength of association between the predictor and
response variables, where a large b indicates a strong
association. A positive b indicates a positive association
between the predictor and response variables, whilst a
negative b indicates a negative association.
T h eO Ri su s e dt oa s s e s st h er i s ko fap a r t i c u l a ro u t -
come if a certain factor (or exposure) is present, indicat-
ing how much more likely it is that someone who is
exposed to the factor under study will develop the out-
come as compared to someone who is not exposed. If
the odds are greater than 1, then the event is more
likely to happen than not, whilst if the odds are less
than 1, then the event is less likely. One ‘reads’ the risk
ratios in precisely the same way.
The results of the univariate and multivariate analyses
were consistent, and for clarity and brevity only the
results of BLR, CR and Kaplan-Meier analyses are pre-
sented. Throughout the analyses the null hypothesis was
rejected at an a level of 10% (P < 0.10), and observa-
tions considered to be marginal (that is, worthy of
further analysis) for an a level between 5% and 10%
(0.05 ≤ P ≤ 0 . 1 0 )a n ds i g n i f i c a n ta t5 %( P <0 . 0 5 ) .T h e
P value represents the probability of error that is
involved in accepting our observed result as valid. For
example, P = 0.05 indicates that there is a 5% probabil-
ity that the relation between the variables found in the
sample occurred by chance.
Results
p53b and p53g isoform expression in primary breast
cancers
Cancers from 127 women (median age, 60.0 years; age
range, 32.1 to 89.1 years) were examined. The majority
of cancers were ductal carcinomas at 84% (107 of 127).
Of these cases, 77% (98 of 127) were ER-positive, 62%
(79 of 127) were PR-positive, 14% (17 of 119) were
HER2-positive and 22% (28 of 127) had a tumour con-
taining mutant p53. Approximately 50% (63 of 127) of
the patients had axillary lymph node metastasis;
tumours were grade 1 (16 cancers), grade 2 (48 cancers)
or grade 3 (61 cancers), respectively. This patient popu-
lation was therefore representative of symptomatic pri-
mary breast cancers in a Western country.
Expression of p53b and p53g was successfully analysed
in the 127 primary breast cancers by using RT-PCR
(Figure 1). On testing in triplicate, breast cancers consis-
tently demonstrated p53b expression (36%; 46 of 127)
and p53g expression (37%; 47 of 127). Only 19% (24 of
127) of tumours expressed both p53b and p53g.
Univariate statistical analysis determined that both
p53b and p53g were associated with clinical markers
(data not shown). To clarify these associations and adjust
for possible confounding variables, BLR analyses were
performed to examine the associations of the various
clinical markers with p53b and p53g (Tables S2 and S3
in Additional file 1). p53b isoform expression was inde-
pendently associated with p53g expression (P = 0.008,
BLR) (Table 1), and p53g expression was independently
associated with p53 mutation (P = 0.002, BLR) (Table 1).
However, after adjusting for other associated clinical mar-
kers, p53b expression was not associated with p53 muta-
tion (P = 0.970, BLR) (Table 1). For tumours bearing the
p53 mutation, p53g cDNA was directly sequenced using
Sanger methods and was found to contain the same p53
mutation identified by the AmpliChip p53 Test, indicat-
ing that p53g was expressed by tumour tissue from the
same allele as the p53 mutation and not by stromal tis-
sues. Most p53 mutations were hemizygous missense
mutations affecting the DNA-binding domain of p53.
Since the p53 gene was mutated at different codons in
our cohort of breast cancer, there were not enough cases
with the same p53 mutation for the statistical analysis.
p53b and p53g isoform expression, clinical and
pathological associations
p53b expression was independently associated with ER
status (P = 0.033, BLR) (Table S4 in Additional file 1),
but not with PR status. p53g expression was not asso-
ciated with either ER or PR status. p53b and p53g iso-
form expression was not associated with tumour type,
menopausal status, age of cancer onset or HER2 status
(data not shown).
As expected, p53 mutation was independently asso-
ciated with cancer recurrence and death (P = 0.013 and
P = 0.017, respectively; BLR) (Table 1). However, neither
p53b nor p53g isoform expression was associated with
cancer recurrence (P = 0.198 and P = 0.636, respec-
t i v e l y )( T a b l e1 )o rd e a t h( P =0 . 0 8 2a n dP =0 . 7 8 3 ,
respectively) (Table 1).
To determine whether the associations between p53
mutation and the various clinical markers were different in
p53b-o rp 5 3 g-positive tumours, data were stratified by
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formed to examine the associations between markers in the
p53b-a n dp 5 3 g-positive and p53b-a n dp 5 3 g-negative
cohorts (Table 2, and Tables S2 and S3 in Additional file 1).
Regarding p53b, p53 mutation status was marginally
associated with cancer recurrence and death in the
p53b-negative cohort (P = 0.059 and P = 0.072, respec-
tively; BLR) (Table S2 in Additional file 1), while in the
p53b-positive cohort p53 mutation status was not asso-
ciated with death but was associated with cancer recur-
rence (P = 0.018, BLR; Table S2 in Additional file 1).
Regarding p53g, p53 mutation status was indepen-
dently associated with cancer recurrence and death in
the p53g-negative cohort (P =0 . 0 0 1a n dP =0 . 0 0 2 ,
respectively; BLR) (Table 2, and Table S3 in Additional
file 1). Interestingly, p53 mutation status was not asso-
ciated with cancer recurrence or death in the p53g-posi-
tive cohort (P = 0.579 and P = 0.282, respectively; BLR)
(Table 2, and Table S3 in Additional file 1), despite the
greater proportion of grade 3 cancers with p53 muta-
tions (61.5%; 16 of 26) in the p53g-positive cohort com-
pared with the p53g-negative cohort (25.7%; 9 of 35).
These data suggest that p53g expression delineates two
subpopulations of mutant p53 breast cancer patients
with markedly different outcomes.
p53b, p53g and clinical outcome
To investigate the association between p53b or p53g iso-
form expression and the clinical markers in relation to
survival and cancer recurrence, we performed CR ana-
lyses that included p53b,p 5 3 g, p53 mutation status and
clinical markers (Table 3). These analyses demonstrated
the expected associations between prognosis (death and
cancer recurrence) and ER, PR, tumour grade, p53
mutation, HER2 or lymph node status (Table 3, rows a-
f), but did not show any independent association for
p53b or p53g isoforms (Table 3, rows g and h).
Further, to determine the degree of interdependence
between the variables p53b, p53g and p53 mutation with
respect to survival and cancer recurrence, we aggregated
these variables into combined variables and reran the CR
analyses. We thus formed a binary variable (p53m&p53b)
that was positive when p53b was expressed and the p53
gene was mutated, but negative otherwise. Similarly, we
formed a binary variable (p53m&p53g) that was positive
when p53g was expressed and the p53 gene was mutated,
but negative otherwise. The results of using such com-
bined variables (Table 3, row i and row j) allowed us to
determine that p53 mutation is no longer associated with
death or cancer recurrence when p53b or p53g is
expressed (Table 3, compare row c with row i or row j).
This effect was independent of ER status and therefore
independent of endocrine therapy (in this study, all ER-
positive patients were treated with tamoxifen 20 mg for 5
years as standard adjuvant therapy). Moreover, there was
also no significant difference in the ER status of patients
bearing p53 mutations between the p53g-positive and
p53g-negative cohorts (P = 0.254, Fisher’s exact test).
Furthermore, given the association between p53b and
p53g expression (Table 1), we performed CR analysis to
determine the combined effects of p53g and p53 muta-
tion in the absence of p53b and reciprocally the com-
bined effects of p53b and p53 mutation in the absence
of p53g. We formed a binary variable (p53m&p53b
+
Figure 1 p53b and p53g mRNA are differentially expressed in primary breast tumours from patient to patient.T o t a lR N Af r o m1 2 7
primary breast tumours were provided by the Tayside Tissue Bank. RNA quality was assessed, and reverse transcription was performed as
described in Materials and methods. The p53 cDNA were amplified by polymerase chain reaction (PCR) assays using primers specific for p53,
p53b and p53g, as shown in Table S1 in Additional file 1. Amplification of actin cDNA by PCR assay was used as a positive control. Tumour
sample numbers are indicated. C, negative control; M, molecular marker.
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-) that was positive when p53b was expressed in the
absence of p53g expression and the p53 gene was
mutated (Table 3, row k). We also formed a binary vari-
able (p53m&p53g
+ p53b
-)t h a tw a sp o s i t i v ew h e np 5 3 g
was expressed in the absence of p53b expression and
the p53 gene was mutated (Table 3, row l). These ana-
lyses revealed that p53 mutation in patients expressing
p53b but not p53g retained the association with death
and cancer recurrence (Table 3, compare row c, row i
and row k), while p53 mutation in patients without
p53b but with p53g was not associated with death and
cancer recurrence (Table 3, row c, row j and row l).
Therefore, the apparent abrogation of the association
of p53 mutation with poor prognosis in the p53g-posi-
tive population (but not in the p53b-positive population)
indicates that only p53g allows the identification of a
subpopulation of breast cancer patients expressing
mutant p53 with a better prognosis than expected.
p53b, p53g expression, p53 mutation and clinical
outcomes
Using Kaplan-Meier log-rank analyses, patients with
mutant p53 breast cancer had significantly worse dis-
ease-free survival and overall survival than those with
wild-type p53 breast cancer (Kaplan-Meier log-rank test,
c
2 =1 0 . 5 1 ,1df, P =0 . 0 0 1 ;a n dc
2 =6 . 5 5 ,1df, P =
0.010, respectively) (Figure S1 in Additional file 3), with
a more than three times increased risk of recurrence
and death (hazard ratio (HR) = 3.48 and HR = 3.16,
respectively). Expression of p53b or p53g was not asso-
ciated with cancer recurrence (Kaplan-Meier log-rank
test, c
2 =0 . 0 5 ,1df, P = 0.817; Figure S2 in Additional
file 4, bottom; and c
2 = 0.15, 1 df, P = 0.694; Figure S3
in Additional file 5, bottom, respectively) or with overall
survival (Kaplan-Meier log-rank test, c
2 = 0.37, 1 df, P =
0.544; Figure S2 in Additional file 4, top; and c
2 =0 . 3 1 ,
1 df, P = 0.575; Figure S3 in Additional file 5, top,
respectively).
Patients bearing mutant p53 tumours and expressing
the p53g isoform had disease-free survival and overall
survival that were not different from patients bearing
wild-type p53 tumours, with a low comparative risk of
recurrence and a similar risk of death (HR = 1.72 and
HR = 1.04, respectively) (Figure 2A: Kaplan-Meier log-
rank test, c
2 = 0.76, 1 df, P = 0.384; and Figure 2B:
Kaplan-Meier log-rank test, c
2 < 0.01, 1 df, P = 0.958,
respectively). However, patients bearing mutant p53
tumours without p53g isoform expression had a high
risk of recurrence and subsequent high risk of death
(HR = 7.21 and HR = 11.23, respectively) compared
Table 1 p53b and p53g expression is associated with
clinical markers
All data
Response
variable
Predictor
variable
b P
value
OR (95% CI)
p53b p53g 1.01 0.008 2.75 (1.29 to 5.84)
p53g p53m 1.47 0.002 4.33 (1.74 to 10.78)
p53b 1.01 0.012 2.74 (1.24 to 6.04)
p53m p53g 1.74 0.002 5.70 (1.92 to 16.93)
p53b -0.02 0.970 0.98 (0.28 to 3.43)
Tumour grade 3 2.85 <0.001 17.31 (4.02 to
74.45)
ER -2.74 0.019 0.06 (0.01 to 0.64)
PR 2.51 0.032 12.27 (1.25 to
120.74)
Overall survival p53m -1.44 0.017 0.24 (0.07 to 0.78)
PR 1.48 0.014 4.41 (1.34 to 14.45)
Tumour size -1.22 0.036 0.29 (0.09 to 0.93)
p53g -0.18 0.783 0.83 (0.22 to 3.10)
p53b 1.15 0.082 3.17 (0.87 to 11.60)
Cancer p53m 1.25 0.013 0.29 (0.11 to 0.76)
recurrence PR -1.26 0.009 3.52 (1.37 to 9.04)
p53g -0.28 0.636 1.33 (0.41 to 4.30)
p53b -0.74 0.198 2.10 (0.68 to 6.47)
Variables were analysed using binary logistic regression analysis utilising the
backwards stepwise elimination method. Lymph node status, tumour grade,
p53 mutation status (p53m), p53b, p53g, human epidermal growth factor
receptor 2 (HER2 or ErbB2), oestrogen receptor (ER) and progesterone
receptor (PR) expression were included in the analyses as predictor variables.
All independent significant associations between the predictor and response
variables were identified (results of run 1). Dependent associations (results of
runs 2, 3, 4, and so on) are omitted. Only results related to p53 and clinical
outcome are presented. Results related to ER/PR, tumour grade and lymph
node status are presented in Table S4 in Additional file 1. The b coefficients
and the odds ratios (OR) with 95% confidence intervals (95% CI) are indicated.
Table 2 p53g expression abolishes the association of p53
mutation status with poor prognosis
p53g
- cohort
Response
variable
Predictor
variables
b P OR (95% CI)
Overall survival p53m -2.70 0.002 0.07 (0.01 to
0.37)
Cancer recurrence p53m 2.77 0.001 0.06 (0.01 to
0.34)
p53g
+ cohort
Overall survival Nothing associated
Cancer recurrence Nothing associated
Variables were analysed using binary logistic regression analysis utilising the
backwards stepwise elimination method. Lymph node status, tumour grade,
p53 mutation status (p53m), p53b, p53g, human epidermal growth factor
receptor 2 (HER2 or ErbB2), oestrogen receptor (ER) and progesterone
receptor (PR) expression were included in the analyses as predictor variables.
All independent significant associations between the predictor and response
variables were identified (results of run 1). Dependent associations (results of
runs 2, 3, 4, and so on) are omitted. Only results related to p53 and clinical
outcomes are presented. Results related to ER/PR, tumour grade and lymph
node status are presented in Table S4 in Additional file 1. The b coefficient
and the odds ratio (OR) with 95% confidence intervals (95% CI) are indicated.
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Kaplan-Meier log-rank test: c
2 =1 8 . 3 3 ,1df, P < 0.001;
and c
2 =2 0 . 7 0 ,1df, P < 0.001, respectively). Consistent
with the CR analysis, the Kaplan-Meier log-rank ana-
lyses indicate that p53g allows the identification of a
subpopulation of breast cancer patients expressing
mutant p53 with a better prognosis than expected.
Discussion
The p53 network is thought to be ubiquitously altered in
human cancers, either through mutation of the p53 gene
or through inactivation of p53 protein [1]. In breast can-
cer, it has been difficult to link p53 mutation status to
therapeutic response and clinical outcome, suggesting
that additional factors may affect the p53 network. We
previously reported that the p53 gene expresses at least
nine p53 protein isoforms in normal human tissue,
including p53b and p53g, which are differentially
expressed in breast cancer as in other types of cancer
[13-19]. In this study, we report the analysis of expression
of p53b and p53g in relation to clinical and pathological
markers and disease outcome in a cohort of 127 ran-
domly selected primary breast tumours.
In our cohort, p53b expression was detected in 36% of
the primary breast tumours and was associated with ER
expression but not with disease outcome. p53g expres-
sion was detected in 37% of primary breast tumours and
was associated with p53 gene mutation. The potentially
clinically significant finding was that p53g expression
allowed discrimination between two subpopulations of
patients bearing mutant p53 tumours: (1) patients bear-
ing mutant p53 cancer and expressing p53g who had
disease-free survival and overall survival as good as
patients with wild-type p53 and (2) patients bearing
mutant p53 tumours without detectable p53g isoform
expression who had a particularly poor prognosis.
Importantly, there was no significant difference in the
ER status of patients bearing p53 mutations between the
p53g-positive and p53g-negative cohorts (P =0 . 2 5 4 ,
Fisher’s exact test). Therefore, the better outcomes of
the breast cancer patients expressing p53g and mutant
p53 a r en o td u et oe n d o c r i n et h e r a p yi nE R - p o s i t i v e
cancers.
We have chosen to perform this analysis without pre-
viously classifying tumours according to immunohisto-
chemical phenotype (luminal (A and B), HER2, basal
(triple-negative: ER
-,P R
-,H E R
-) and unclassified)
because, in our cohort, the low number of tumours in
each immunohistochemical phenotype did not allow us
to perform CR and Kaplan-Meier log-rank analyses to
investigate p53 isoform expression in relation to clinical
outcome. Indeed, among the 85 luminal tumours (ER
+,
PR
+ and HER
-), only 10 tumours expressed mutant p53.
This low number of p53 mutations did not allow us to
find a significant statistical association between p53
isoform expression and p53 mutation. By contrast,
Table 3 Cox regression analyses: p53 mutation status in p53 mutant breast cancer patients expressing p53g is not
associated with death and cancer recurrence
Death Recurrence
ID Run Predictor b P RR (95% CI) Run Predictor b P RR (95% CI)
a 1 Tumour grade 3 2.12 0.005 8.33 (1.90 to 36.47) 1 PR -0.99 0.021 0.37 (0.16 to 0.86)
b 2 PR -1.36 0.011 0.26 (0.09 to 0.74) 1 p53m 1.06 0.012 2.87 (1.27 to 6.51)
c 2 p53m 1.1 0.026 3.00 (1.14 to 7.85) 2 Tumour grade 3 1.51 0.003 4.52 (1.60 to 12.11)
d 3 ER -1.54 0.002 0.21 (0.08 to 0.55) 3 HER2 1.16 0.012 3.18 (1.29 to 7.83)
e 4 HER2 1.21 0.026 3.35 (1.16 to 9.65) 4 ER -1.05 0.012 0.35 (0.16 to 0.79)
f5
b Lymph nodes 1.19 0.037 3.30 (1.08 to 10.13) 5
b Lymph nodes 0.93 0.039 2.53 (1.05 to 6.09)
g6
b p53b -0.38 0.491 0.69 (0.24 to 2.00) 6
b p53b -0.17 0.699 0.84 (0.35 to 2.03)
h6
b p53g 0.48 0.337 1.61 (0.61 to 4.29) 6
b p53g 0.19 0.652 1.21 (0.52 to 2.81)
i5
b p53m&p53b
+ 0.07 0.451 1.47 (0.54 to 3.99) 5
b p53m&p53b
+ 0.97 0.053 2.65 (0.99 to 7.10)
j5
b p53m&p53g
+ 0.31 0.626 1.36 (0.39 to 4.75) 5
b p53m&p53g
+ 0.49 0.333 1.63 (0.61 to 4.36)
k 2 p53m&p53b
+ p53g
- 2.87 0.017 17.56 (1.66 to 186.15) 4 p53m&p53b
+&p53g
- 1.71 0.021 5.51 (1.29 to 23.57)
l5
b p53m&p53g
+&p53b
- 0.78 0.298 2.19 (0.50 to 9.59) 5
b p53m&p53g
+&p53b
- 0.31 0.679 1.36 (0.32 to 5.78)
aVariables were analysed using Cox proportional hazards regression model utilising the backwards stepwise elimination method. Lymph node status, tumour
grade, p53 mutation status (p53m), p53b, p53g, human epidermal growth factor receptor 2 (HER2 or ErbB2), oestrogen receptor (ER) and progesterone receptor
(PR) expression were included in analyses as predictor variables. The run number refers to the run in which the predictor variable was deemed to be statistically
significantly associated with the response variable (death or recurrence) and thereafter was excluded from further runs. Rows a-f refer to the statistically
significant results in the first iteration of analyses without interaction variables. Of the variables that were not associated with the response variables, p53b and
p53g are included in the table (rows g and h), but others are omitted for clarity and brevity. Rows i-l refer to results of Cox regression analyses for the interaction
predictor variables shown in the presence of all the above predictor variables (data not shown for clarity and brevity). The b coefficient and the risk ratio (RR)
with 95% confidence intervals (95% CI) are indicated;
bFinal run in a given set of analyses.
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Page 6 of 10Figure 2 p53 mutant breast cancer patients expressing p53g have disease-free survival and overall survival comparable to that
of patients bearing wild-type (wt) p53 breast cancer. Nonparametric Kaplan-Meier plots for p53g expression and p53 gene mutation of
(A) disease-free survival (n = 125) and (B) overall survival (n = 122). Censored cases are indicated by ‘l’ on the curves. P values are indicated.
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Page 7 of 10regarding patients who were not in the luminal group
(basal and unclassified tumours), 13 of 16 tumours with
a p53 mutation expressed p53g (81%), whilst 14 of 18
tumours with wild-type p53 did not express p53g (78%).
This finding confirms that p53g expression is associated
with p53 mutation status. Regarding patients who were
in the basal group (triple-negative), there was a signifi-
cant positive association between p53g expression and
p53 mutation, with 6 of 7 tumours with a p53 mutation
expressing p53g (86%), whilst 9 of 10 tumours with
wild-type p53 did not express p53g (90%). The result in
nonluminal patients is consistent with the results
obtained without classifying tumours according to
immunohistochemical phenotype. Of note, the lack of
association in luminal patients between p53g expression
and p53 mutation is probably due to the low number of
p53 mutations in this breast cancer subtype.
By sequencing p53g cDNA in breast tumours expres-
sing mutant p53, we noted that p53g cDNA contained
the same mutation as the p53 gene, indicating that p53g
was expressed by the tumour cells and not by cells from
the stroma. Therefore, this finding suggests either that
the mutant p53g isoform has an intrinsic activity abro-
gating the poor prognosis associated with p53 mutation
or that p53g is just an inactive marker of better out-
comes for mutant p53 breast cancer patients. Future
investigations will seek to determine the biological and
biochemical activities of mutant p53g and its interplay
with mutant p53 in tumour cells.
We did not differentiate between the different cate-
gories of p53 mutations (nonsense mutations, missense
mutations, ‘DNA-contact’ mutations or ‘conformational’
mutations), as there were not enough cases in each p53
mutation category for confident statistical analysis.
However, in larger breast cancer cohorts, it would be
interesting to take the different p53 mutation categories
and molecular subtypes of breast cancer into account to
refine the statistical analysis.
Currently, p53g expression can be specifically detected
only by PCR. From a clinical utility perspective, it would
be useful to analyse p53b and p53g expression by using
immunohistochemistry. The mouse monoclonal antibo-
dies DO-1 and DO-7 recognise p53, p53b and p53g,b u t
not the other p53 isoforms. The rabbit or sheep polyclo-
nal p53 antibodies (CM1 and Sapu, respectively) raised
against recombinant full-length human p53 protein
recognize all p53 isoforms, while the KJC8 antibody
recognises specifically all p53b isoforms (that is, p53b,
Δ40p53b and Δ133p53b). However, we have been
unable to stain paraffin-embedded sections using the
KJC8 antibody. Since p53b and p53g can be localised in
both the nucleus and the cytoplasm, we have attempted
to determine by performing immunohistochemistry on
paraffin-embedded breast tumour sections using DO-1
or CM1 p53 antibodies whether p53b or p53g expres-
sion is associated with cytoplasmic or nuclear staining.
There was no significant association between p53 cyto-
plasmic or nuclear staining by DO-1 or CM1 and p53b
or p53g expression. Pending the generation of isoform-
specific antibodies, p53 immunostaining on tumour sec-
tions should be interpreted with caution and should be
complemented by PCR analysis to determine p53 iso-
form mRNA expression in tumours.
Treatment influences were not identified in this analy-
sis, although no taxane, cisplatin or trastuzumab therapy
was administered to the patients studied, and anthracy-
cline-based chemotherapy was the standard agent used
during the sample accrual period. p53 mutation may be
associated with resistance to several chemotherapy
agents; but p53 mutant breast cancer may be more sen-
sitive to taxanes, at least in the neoadjuvant setting
[5-10], and the predictive value of p53 mutational status
in breast cancer remains controversial [3,4]. The influ-
ence of the p53g isoform in the setting of clinical trials
such as the neoadjuvant European Organisation for
Research and Treatment of Cancer (EORTC) 10994
Trial, which is testing the association between p53
mutation and taxane versus anthracycline therapy, mer-
its consideration and would provide potential validation
of the association of the p53g isoform with p53 muta-
tion and prognosis in the setting of a randomized, con-
trolled trial. In addition, since mutant p53 cancers are
generally of basal or triple-negative phenotype, the influ-
ence of the p53 isoforms on platinum therapies and poly
(ADP-ribose) polymerase inhibitors in appropriate clini-
cal trials would be of interest. Meanwhile, the apparently
dominant effects of the p53g isoform influencing the
p53 network may provide an explanation for the con-
flicting literature regarding the clinical associations
between mutant p53 and breast cancer and issue a
warning that clinical decisions made on the basis of p53
mutation status alone may need to be approached with
caution.
Conclusions
In this report, the expression of the p53b and p53g iso-
forms was examined in relation to clinical and patholo-
gical markers, p53 mutation and disease outcome in a
cohort of 127 randomly selected primary breast
tumours. We determined that p53b and p53g isoform
expression is associated, respectively, with ER status and
p53 mutation. p53b or p53g isoform expression is not
independently associated with overall survival or dis-
ease-free survival. On the basis of multivariate analyses
and Kaplan-Meier analyses, we determined that the
breast cancer patient group expressing both mutant p53
and the p53g isoform has a disease-free and overall sur-
vival as good as the patient group bearing wild-type p53
Bourdon et al. Breast Cancer Research 2011, 13:R7
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Page 8 of 10breast cancer. Conversely, patients expressing only
mutant p53 without p53g isoform expression had a par-
ticularly poor prognosis. The p53g isoform may explain
the inconsistent relationship between p53 mutation and
breast cancer reported in the literature.
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